Review concluded regarding general reimbursement for Multaq®

16 January 2012

The Danish Medicines Agency has completed its review of an application for general reimbursement for Multaq®. The product is neither eligible for general nor general conditional reimbursement.

Multaq® is used for the treatment of patients with atrial fibrillation.

When we compare Multaq® with certain other medicines used to treat atrial fibrillation, we assess that the price of the medicine is not reasonable relative to its therapeutic value.

The reimbursement status of Multaq® will be reassessed in connection with the regular reassessment of the reimbursement status of all medicines.

Please find the Reimbursement Committee recommendation and the Danish Medicines Agency’s decision in the box to the right (in Danish only).

Did you get answers to your questions?

Please tell us how we can improve our website? Please note that we do not answer questions asked via this feature.